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ARTICLE OPEN
Missense-depleted regions in population exomes implicate ras
superfamily nucleotide-binding protein alteration in patients
with brain malformation
Xiaoyan Ge1,2, Henry Gong1,2, Kevin Dumas1,2, Jessica Litwin3,4, Joanna J Phillips5,6, Quinten Waisfisz7, Marjan M Weiss7,
Yvonne Hendriks7, Kyra E Stuurman7, Stanley F Nelson8, Wayne W Grody9, Hane Lee10, Pui-Yan Kwok2,11,12 and Joseph TC Shieh1,2
Genomic sequence interpretation can miss clinically relevant missense variants for several reasons. Rare missense variants are
numerous in the exome and difficult to prioritise. Affected genes may also not have existing disease association. To improve variant
prioritisation, we leverage population exome data to identify intragenic missense-depleted regions (MDRs) genome-wide that may
be important in disease. We then use missense depletion analyses to help prioritise undiagnosed disease exome variants. We
demonstrate application of this strategy to identify a novel gene association for human brain malformation. We identified de novo
missense variants that affect the GDP/GTP-binding site of ARF1 in three unrelated patients. Corresponding functional analysis
suggests ARF1 GDP/GTP-activation is affected by the specific missense mutations associated with heterotopia. These findings
expand the genetic pathway underpinning neurologic disease that classically includes FLNA. ARF1 along with ARFGEF2 add further
evidence implicating ARF/GEFs in the brain. Using functional ontology, top MDR-containing genes were highly enriched for
nucleotide-binding function, suggesting these may be candidates for human disease. Routine consideration of MDR in
the interpretation of exome data for rare diseases may help identify strong genetic factors for many severe conditions,
infertility/reduction in reproductive capability, and embryonic conditions contributing to preterm loss.
npj Genomic Medicine (2016) 1, 16036; doi:10.1038/npjgenmed.2016.36; published online 5 October 2016
INTRODUCTION
Genomic sequencing reveals many rare or private heterozygous
missense variants per person. These rare variants occur across
numerous genes, many of which are not yet associated with any
known human disorder, and prioritising variants1 in the context of
critical genic regions is important for clinical and research
applications. Gene alterations responsible for severe human
diseases can limit reproductive fitness. Such alterations thus may
not be propagated in the population, and therefore coding
regions could demonstrate a lack of functional variation in the
normal adult population due to intolerance to variation as these
variants would have a functional impact.2,3 Along this line, taking
advantage of the selective pressure on the X-chromosome, where
selection pressure would deplete such variation from critical
genes, we previously used normal adult X-chromosome data to
prioritise potential disease genes and found that genes with
missense depletion are more likely to be known human disease
genes.2 Several illustrative studies have explored measures of
variation to examine genic intolerance to variation for predicting
and identifying disease genes,2–5 but whether such concepts
could be applied to specific regions of genes, their proteins, or to
specific modes of inheritance6,7 has not been fully investigated.
As specific regions of a given gene are more important for
function, we rationalise that these can be partially identified as
genomic regions that are devoid of missense variation in the
normal adult population,8,9 and assessment of these regions in an
unbiased manner may yield regions more likely to underlie severe
rare diseases. Therefore, variant depleted intervals of genes
may be intersected with rare missense variants of uncertain
significance in exome data of a given individual to facilitate
interpretation. When we initially examine the variant pattern from
population exome data looking for gene level missense depletion,
although the overall missense depletion is modest in disease
genes, the greatest difference is seen in genes for dominant or
X-linked conditions, which are reported to account for approxi-
mately 50% of all diagnoses made for trio clinical exomes.10–12
Therefore, a missense depletion strategy could be very useful for
the large number of dominant/de novo conditions and for
identifying new disorders due to unannotated genes.
To apply this hypothesis of MDRs being more likely to cause a
human disorder when mutated, here we apply missense depletion
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to undiagnosed disease exome data where many rare variants of
uncertain significance are considered for pathogenicity. By
prioritising candidates by missense depletion, we identified a
novel gene association of ARF1 with a human brain malformation.
With ARF1 protein, we demonstrate that missense variation near
the nucleotide-binding site of ARF1 alters activation and places
ARF1 in the pathway of genes that underlie this birth defect.
Importantly, the method described here could be applied more
generally for rare variant prioritisation when searching for
pathogenic variants for human disorders.
RESULTS
Differences in population missense variation are associated with
disease gene inheritance pattern
Genic tolerance to variation is useful in evaluating disease gene
candidates, especially for candidate genes with loss of function
variants. Missense variants, however, are remarkably numerous in
the exome, and these variants may be neutral, positive or
deleterious depending on the amino acid and the position of
the variant within the gene. Such distinction of inferred variant
function is essential in predicting the pathogenicity of the variant.
However, missense variants are often rare and lack meaningful
prior annotation increasing reliance on in silico prediction
programs such as Polyphen-2 and SIFT. Therefore, alternative
methods are needed for evaluating variants and genes for
pathogenicity regardless of previous disease annotation or
whether a variant has been seen before.
We and others previously utilised missense-to-synonymous
variant ratios in control population exomes (using dN/dS, which
also accounts for sequence composition) to predict disease
causing genes2,3 but the role of specific gene regions is relatively
unexplored.2 Several studies have identified disease genes that
were predicted by our X-chromosome methods.13,14 When we
examine all disease genes genome-wide, they show a modest but
significant difference in per-gene dN/dS compared with genes not
yet associated with any rare disease (Supplementary Figure 1).
These data support the idea of disease genes being more likely to
be missense-depleted in the population data. When we analyse
known disease genes by disease inheritance pattern, we find that
genes causing autosomal dominant or X-linked conditions have
Figure 1. Missense depletion of genes by disease inheritance
pattern. Violin plots of dN/dS for disease genes by inheritance
annotation (OMIM and Orphanet). AD, autosomal dominant;
AR, autosomal recessive, XL, X-linked. Po2.2e− 16, Kruskal–Wallis
rank sum test.
Figure 2. Missense-depleted regions in genes using population exomes. (a) Missense variant site density plots along the coding sequence
length of ACTB or SMARCA4 from ~6,500 sequenced exomes from ESP. Grey-shaded regions indicate candidate missense-depleted regions
(MDRs) that lack missense variants but that have synonymous variants. (b) Missense variant plots for ACTB and SMARCA4 using ~ 60,000
exomes from ExAC data, further delineate MDRs. (c) Density plots of pathogenic missense variant sites from ClinVar.
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significantly lower genic dN/dS compared with those causing
recessive conditions (Figure 1). These results suggest selection
against missense variants can be seen in disease genes and seen
more significantly in genes where a single-allele deleterious
variant is sufficient to lead to a significant phenotype. Given the
large portion of exome diagnoses that result from dominant/de
novo variation,10–12 applying missense depletion in prioritising
novel candidate genes may be particularly useful even when gene
function is unknown or potentially when parental sequence is not
available. Importantly, we surmised that the observed missense
variant frequency could also vary locally, encompassing not only
entire genes but also portions of genes.2
Missense-depleted regions in coding regions of the genome
Hypothesising that genic regions responsible for severe conditions
would be depleted of missense variations and could identifying
such intragenic regions could lead to finding candidate genes for
new dominant conditions in the exome, we analysed all genes in
population data from the NHLBI exome sequencing project (ESP)
for missense-depleted regions (MDRs).
We analysed 18,593 human coding genes and identified genes
harbouring missense-depleted regions (defined as at least 300
contiguous base pairs lacking missense variation but harbouring
synonymous variants, Methods). One hundred twenty eight genes
were identified with regions that completely lacked missense
variation. Only 40 of the 128 (31.2%) of these were in genes with
known OMIM disease. Plotting missense variation as a function of
gene region, distinct segments of coding regions lacked missense
variation. These regions can be identified as illustrated in genes
such as ACTB and SMARCA4 using the ESP population exome data
(Figure 2a), including, for example, crucial nucleotide-binding
domains. Further assessment of these Missense-Depleted Regions
(MDRs) was performed by considering ExAC data (Exome
Aggregation Project) that also includes some of the NHLBI ESP
data and increases the number of variants from population exome
data (Figure 2b), and MDRs were apparent in ACTB and SMARCA4,
further refining the region. When the locations of known
pathogenic mutations for the corresponding syndromes (ACTB,
associated with Baraitser–Winter and SMARCA4, associated with
Coffin–Siris),15–18 were plotted on the coding sequence, the
pathogenic variants overlapped with the MDRs (Figure 2c). These
results suggest missense-depleted regions in the genome can be
informative for understanding variant effects and for prioritising
potential disease variants. MDRs could reveal new candidates for
disease in genes/gene regions not yet associated with disease.
Indeed, the majority of MDRs are not yet annotated with any
human disease. We examined MDR-containing genes using GTEx
and 65 of the 128 (51%) were highly expressed in the brain.
We provide a list of MDRs identified in the exome and also
include genes with overall gene depletion of missense variation
(Supplementary Tables 1 and 2). Of the 128 MDR-containing
genes, most of the genes are intolerant to loss of function as well
(Supplementary Figure 2); however, select genes had loss of
function variants (pLIo0.01), suggesting the mechanism of action
of deleterious missense variation in select genes is not due to
haploinsufficiency. 88% of the cannonical genes had overlap with
conserved protein domains.
Given that MDRs identified in the exome could signify
important disease gene candidates, we assessed whether genes
with MDRs were enriched for any particular molecular functions.
Genes with MDRs were highly enriched in nucleotide binding by
functional annotation using gene ontology; the top ten enriched
terms are shown (Table 1). Thus, nucleotide-binding proteins may
be candidates for rare disease and have particular portions that
are highly likely to be pathogenic when mutated. We then
performed Earthmover's distance (EMD) analysis19 (Materials and
Methods) as an additional measure to discern differences in
distribution of missense and synonymous variants within genes
(Supplementary Figure 3 and Supplementary Table 3). We
hypothesised that current human exome testing for undiagnosed
disease could potentially benefit from testing our observations
about patterns of variation. Rare variation within MDRs may need
to be prioritised for functional characterisation as disease
candidates, and a missense depletion measure could be
integrated into exome analyses, potentially increasing the overall
diagnostic yield.
Application to undiagnosed disease exome data
In exome sequencing, a list of filtered variants often
includes multiple variants in genes unannotated for disease.
We hypothesised that application of missense depletion could be
used to prioritise variants in rare undiagnosed disease exome
data regardless of knowledge of gene function. Importantly,
prioritisation of variants could be performed initially independent
of phenotype and considering all rare variants from a proband.
To test this, exome sequencing was performed for diagnostic
testing for a 9-year-old boy with developmental disability and
attention deficit hyperactivity who previously had non-diagnostic
genetic tests. Large copy-number variant testing was negative
by SNP microarray, and there was no family history of develop-
mental disability. A brain MRI revealed periventricular nodular
heterotopia.
Sequencing from the proband yielded a mean coverage of
108 × and resulted in 23,323 variants: 22,026 single-nucleotide
variants and 1,297 small insertions and deletions (indels). After
filtering for amino-acid changing and rare (minor allele frequency
o1% in NHLBI ESP population) variants, 480 variants remained.
We considered all these variants from the proband exome
regardless of prior gene–disease annotation and applied our
missense-depletion analysis methods. First, each of the variants
Table 1. Enrichment of MDR-containing genes for gene ontology terms
Category Terma P-value Fold Bonferroni
MF GO:0000166 nucleotide binding 1.05e− 07 2.17 1.13e− 04
MF GO:0032553 ribonucleotide binding 1.35e− 07 2.34 1.28e− 04
MF GO:0032555 purine ribonucleotide binding 1.35e− 07 2.34 1.28e− 04
CC GO:0043005 neuron projection 4.14e− 07 5.40 1.38e− 04
MF GO:0017076 purine nucleotide binding 2.26e− 07 2.24 3.87e− 04
BP GO:0030001 metal ion transport 1.16e− 06 4.40 6.81e− 04
MF GO:0032559 adenyl ribonucleotide binding 1.76e− 06 2.40 9.79e− 04
BP GO:0006812 cation transport 5.33e− 07 3.92 1.54e− 03
MF GO:0046873 metal ion transmembrane transporter activity 2.74e− 06 4.75 1.91e− 03
MF GO:0005524 ATP binding 3.52e− 06 2.36 2.18e− 03
Abbreviations: BP, biological process; CC, cell compartment; GO, gene ontology; MF, molecular function.
aTop 10 highest enriched terms are listed.
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was ranked by the corresponding gene overall missense depletion
score. Second, each variant-affected gene was also prioritised by
its intragenic missense distribution score, EMD, which suggested
potential for MDR in the coding region. Either of these methods
could be useful in prioritising potential disease-related variants.
Interestingly, the distribution of the 480 proband variant-affected
genes revealed two genes that were the most missense-depleted:
ARF1 showed the highest priority by missense depletion (Figure 3,
Supplementary Table 4), followed by SOD1. By intragenic missense
distribution score (EMD), SEPT7 was the highest priority followed
by ARF1 (Figure 3, Supplementary Table 4); SOD1 ranked 4th by
EMD. ARF1 and SEPT7 had rare heterozygous variants. SEPT7,
affected by a missense variant, ranked poorly however by overall
missense depletion, at 451st rank, compared to ARF1 or SOD1.
Homozygous, mitochondrial and X-linked variants were also
considered, but these variants either were found previously in
controls or the genes did not rank highly by missense depletion
or EMD.
To further examine missense variants in ARF1 and SEPT7, variant
locations from the patient exome were examined on variant
distribution plots from population exome data (to assess overlap
with MDRs). The proband's missense variant in SEPT7 did not
co-localise with the distal MDR in SEPT7 and was in a region of
frequent population missense variation. In contrast, the proband's
ARF1 missense variant (c.103T4C (p.Y35H) NM_001024226)
corresponded within the population-data-observed MDR of ARF1
(Supplementary Table 5). These results indicate that ARF1
demonstrates missense depletion in population exome data
gene-based analysis and also localised missense depletion. Given
these findings, the proband missense variant in ARF1 could be
important in disease.
When we added parental exome sequence data (trio analysis
including proband), de novo and compound heterozygous
variants in the proband could also be readily discerned. ARF1
was among three genes affected by de novo variants, and of the
de novo-affected genes (Supplementary Table 6), ARF1 was the
most outstanding by missense depletion prioritisation using
population data (Supplementary Figure 4). The proband's SOD1
and SEPT7 variants were inherited from unaffected parent, making
these less likely to be pathogenic variants. Analysis of compound
heterozygous variant-affected genes (FLG, C10orf92, DNAH2 and
ABCA5) did not reveal other high-priority candidates by missense
depletion analyses. The addition of parental data supported the
initial findings from proband-only prioritisation by missense
depletion. ARF1 was the top candidate both by proband and by
trio analysis. In addition, no variants were observed in the known
or possible genes for periventricular heterotopia including FLNA,
ARFGEF2 and ERMARD, nor were pathogenic variants seen in other
known genes implicated for brain malformation syndromes,
intellectual disability or ADHD conditions.
De novo ARF1 variants in patients with brain malformation
We analysed other population variants reported in this gene to
further evaluate ARF1 as a novel disease-associated gene.
ARF1 lacks stop, splice-site or cryptic start variants (predicted
high-confidence loss of function) in the NHLBI ESP and in ExAC,
however ARF1 has 8 sites of missense variation in ExAC with one
variant observed in 17 individuals in the proximal part of the gene
c.16G4A (p.A6T). Examination of the testing lab database also
revealed a missense variant that was also reported in ExAC,
and this individual did not have the same symptoms as the
proband here. We additionally examined both Genome of the
Netherlands data, 769 exomes,20 and Icelander sequencing data,
2636 genomes,6 and did not find missense variation in ARF1.
To understand the potential functional role of the rare
population variants in ARF1 and from the neurologic phenotype,
we examined all these variants on the ARF1 crystal structure
(Figure 4a,b). ARF1 is a RAS-superfamily GDP nucleotide-binding
protein that leads to GDP/GTP conversion and GTP-activation of
ARF1 with the help of ARFGEFs. Interestingly, our undiagnosed
patient's c.103T4C (p.Y35H) variant is located adjacent to the
GDP-binding site of ARF1 and Y35 is predicted by ligand
prediction method LPC/CSU (Materials and Methods) to interact
with GDP-binding site residues. In contrast, population-detected
rare missense variants were localised away from nucleotide-
binding residues.
In addition to the patient with p.Y35H, a second unrelated
individual with periventricular heterotopia with a de novo, rare
Figure 3. Prioritisation of variant-affected genes from the proband.
Comparison of variant-affected genes from the proband (vertical
lines) compared with the distribution for all genes in the exome
(histogram). (a) Evaluation by dN/dS from population exomes, a
lower score indicates higher priority. (b) Evaluation using
Earthmover's distance, a measure for potential MDR-containing
gene. Candidates ARF1, SEPT7 and SOD1 are highlighted in coloured
vertical lines.
Figure 4. Localisation of variants on ARF1. In blue, location of de
novo heterozygous c.103T4C (p.Y35H), de novo heterozygous
variant c.296G4A (p.R99H), and de novo heterozygous c.379A4G
(p.K127E) from cases. De novo missense variants in ARF1 from brain
malformation cases are localised near the GDP-binding site of ARF1
in contrast to the variants found in the ExAC population (dark grey
numbers). Colours: ARF1 (orange) and the ARFGEF Sec7 domain,
GDP (light blue) and Mg2+. (a, b) are different views of ARF1.
Structure from protein database accession 1R8Q.
Missense-depleted regions in population exomes and brain
X Ge et al
4
npj Genomic Medicine (2016) 16036 Published in partnership with the Center of Excellence in Genomic Medicine Research
missense variant in ARF1, c.379A4G (p.K127E) was also found.
This variant affects an amino-acid residue in the predicted ARF1
GDP-nucleotide binding site by LPC/CSU analysis (Figure 4 and
Supplementary Table 7). In addition, the affected residue p.K127 is
known to be important in functional studies of ARF1 in other
systems.21,22 A third patient had a de novo missense variant in
ARF1 c.296G4A (p.R99H) and had brain malformation with
delayed myelination in childhood and significant cerebral under-
development 12 years later, and p.R99 appears to contact two of
the GDP-binding residues of ARF1 by LPC/CSU analysis (Figure 3
and Supplementary Table 7). The three ARF1 missense variants
were in MDR (Supplementary Figure 5). The initial patient on exam
had a head circumference of 60th centile, weight of 70th centile,
height of 60th centile. He was born at term. He had a history of
otitis media and developmental delay especially in speech, he did
not have a history of seizure, although he had an EEG in the past.
The MRI brain showed periventricular heterotopia and diminished
white matter. The second patient had delays, particularly in
speech and seizures. When she was seen at 15 years she had a
head circumference was 5th centile, the weight was 20th centile,
height 3th centile and she had spasticity and had regressed in
language abilities. The MRI showed delay in myelination and
cortical thinning and vermis atrophy. The third individual had
limited information available but had seizures and periventricular
heterotopia.
These results further emphasise the importance of variant
prioritisation based on the location of intragenic missense
variants, nucleotide-binding proteins and missense depletion
regions. Given that the variant p.Y35H in ARF1 was untested but
would be predicted to affect GDP/GTP activation and lies in the
G4 loop adjacent to the ARF1 switch region, we directly tested its
effect on ARF1 protein activity. We used site-directed mutagenesis
to introduce the variant for p.Y35H into ARF1 cDNA and verified
this by sequencing prior to transfection. Wildtype and
p.Y35H-altered ARF1 were expressed in 293T cells at similar levels.
As opposed to wildtype, however, p.Y35H ARF1 was markedly
reduced in nucleotide activation (Figure 5), thus verifying that the
missense variation predicted to affect the GDP site was
deleterious.
Taken together, these results suggest decreased activation of
ARF1 could be an important factor in disease in the brain.
Mutations in ARF1 have not been associated with disease prior to
this report. Interestingly, ARF1 is likely in a molecular pathway with
known genes for periventricular heterotopia including FLNA and
ARFGEF2, the gene encoding the ARF-activator protein BIG223.
These results indicate that exome variants may be prioritised
using missense depletion methods from population exome data
independent of knowledge of a gene or gene region's function.
This information combined with functional data can yield new
insights into the role of rare variants in human disease.
DISCUSSION
Medical exomes have tremendous diagnostic potential, but key
genetic contributors to disease are elusive in more than half
of patients. A significant challenge is interpreting the many
rare variants that lack gene/disease annotation. While further
sequencing will continue help to identify more variants in the
human exome, we demonstrate here a methodology using
population missense depletion data to help interpret exome
results and prioritise missense variants more likely to have a
functional consequence. We demonstrate how variants from
exome testing can be examined independent of phenotype. Using
these methods, we discover de novo ARF1 missense variants
that affect the protein proximal to its nucleotide-binding site.
Moreover, our results suggest decreased ARF1 activity is seen with
the brain malformation, and this supports a new potential gene
association.
As a known Ras-superfamily GDP/GTP exchange protein,
ARF1 is a class I Arf important in membrane traffic24 and in
mediating COPI vesicle formation. Found in neuronal processes,
ARF1 also affects cellular cytoskeletal regulation,25–27 as does the
X-chromosome encoded FLNA. The identification of ARF1 variants
here suggests an effect in brain development and further extends
the FLNA-associated pathway in periventricular heterotopia.28–30
Interestingly, mutations in ARFGEF2 encoding BIG2 has been
associated with recessive periventricular heterotopia, and these
predict loss of ARF-activation in the disorder. On the basis of our
functional data, our results also support haploinsufficiency of the
ARF pathway leading to brain malformation in these patients.
Levels of ARF1 activity may be important to examine further since
complete loss of function is embryonic lethal.31 The 1q42 genomic
region, where ARF1 resides, has also been implicated in brain
development and white matter abnormalities, and our studies add
ARF1 to the candidates that could influence the brain.32 Future
attention to ARF1 and other GTPases could assist in our
understanding neuronal pathogenesis and other intellectual
disabilities. Furthermore, our results indicate that nucleotide-
binding protein genes are enriched in missense-depleted
regions in population exomes. Interestingly, GTPase signalling
and nucleoside metabolism were identified in Uddin et al.8
as pathways important when studying autism spectrum disorder.
Therefore, further attention to these proteins is suggested
when analysing exome variants in significant neurophenotypic
conditions.
The results here show how a prioritisation strategy with MDR
can be used in analysing exome data. These strategies could
augment variant evaluation methods.1 Missense variants
represent the largest category of variant-type from exome data
and more missense variants will also result from further exome
and genome sequencing, and phenotype-agnostic prioritisation of
these can assist in data interpretation of probands and trios.
Substantial attention can still be given to known gene–phenotype
associations, but we hope to augment the identification of
novel gene–disease association using the methods described. As
aetiologic de novo mutations have been frequent in exomes,5,10,33
we expect that MDRs will further increase exome yield by
annotating portions of genes that are likely to be particularly
deleterious when mutated. Application to de novo dominant
and X-linked conditions may yield new candidate disease genes;
however, the application in recessive disease genes will be limited.
Regions that are missense-depleted in an increasing sequenced
population may represent critical genomic regions that have
significant medical importance. Even in known disease genes,
they may identify new phenotypes associated with variants
in these regions. Furthermore, genetic elements that are
Figure 5. Variant in ARF1 alters nucleotide activation. ARF1
nucleotide activation of wildtype (WT) or p.Y35H ARF1-transfected
293T cells. 293T cells basal ARF1 expression (lane 1), and wildtype
and p.Y35H transfection demonstrate similar ARF1 expression (lanes
2 and 3). Blank (lane 4) Pulldown for GTP-activated ARF1 (lanes 5–9):
Basal activated ARF1 (lane 7). Compared to activated ARF1 levels in
WT (lane 8), p.Y35H variant demonstrates reduced GTP activation
(lane 9). Lanes 1–3 represent the protein expression for the
assay. Lanes 5–6 represent the positive and negative controls
(GTP-gamma-S and GDP, respectively). Result is representative for
three independent transfection experiments with pulldown and
western blotting.
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missense-depleted could underlie multiple types of conditions
with decreased reproductive fitness and therefore could have
even broader clinical utility.
MATERIALS AND METHODS
MDR analysis
Missense-depleted regions (MDRs) were initially identified by analysing all
RefSeq coding sequences (CDS) for regions lacking missense variation in
population data. Population exome variant data were obtained from the
NHLBI GO ESP (Exome Sequencing Project ESP6500SI-V2-SSA137 http://evs.
gs.washington.edu/EVS/; accessed on 25 September 2014) and the ExAC
data (Exome Aggregation Consortium r0.3 ftp://ftp.broadinstitute.org/pub/
ExAC_release/; accessed on 02 February 2015). The ESP data set includes
variants from 6503 exomes. The ExAC data set includes variants from
60,706 exomes (including some from the ESP). ESP exomes are derived
from adults (except for some from cystic fibrosis individuals), while the
ExAC data set excludes data from patients with severe paediatric diseases.
All RefSeq CDS (32,848 transcripts) were analysed for overall and regional
missense depletion by quantifying the missense substitution rate and
synonymous substitution rate within the population. For identifying MDRs
with the most depletion in missense variants, we scanned for coding
regions that lack missense variation using a minimum window size of 300
base pairs length, while requiring the presence of at least 10 synonymous
variants at a frequency of one for every 10-codon group. The size is a strict
criterion for MDRs; we performed analysis for smaller MDRs. With small
regions, these could be subject to a lack of missense variants simply due to
low numbers of variants, and size resolution should improve with further
exome data. We have added Supplementary Figure 6 depicting the
number of candidate regions identified with different MDR size criteria.
Missense depletion was further assessed by screening all CDS, assessing
the differences in missense and synonymous variant distributions along
each CDS length for potential regional missense depletion. CNVs were not
analysed due to limited data. The Earthmover's distance (EMD) was used
here as a regional measure of distance between two probability
distributions based on a Mallows distance with equal masses.19 This
distance represents the energetic cost of transforming one distribution
into another; here we used the distributions of missense and synonymous
variants across each CDS. The EMD was calculated using the emdist
package for R (http://cran.rproject.org/web/packages/emdist/index.html).
Genic dN/dS was also calculated for all transcripts using variants using the
Nei and Gojobori method.34 This method tests whether mutations will
result in synonymous or missense substitutions for each nucleotide in the
coding sequence to determine the number of potential sites in a coding
sequence on a per-codon basis. The total N sites for the sequence is the
sum of the N sites for each codon, and similarly the total S sites is the sum
of all S sites in the sequence. These are combined with the actual observed
N and S sites in the population variant data for dN/dS. EMD and dN/dS
genome-wide statistics from population data were then used to evaluate
all variants from exome data.
Functional analyses
Genes with MDRs were analysed for functional categorisation using the
DAVID Functional Annotation tools (https://david.ncifcrf.gov/). We tested
genes for enrichment (default thresholds: EASE 0.1, count 2) in any gene
ontology term and applied Bonferroni multiple testing correction.
Gene disease annotation and inheritance patterns
Gene annotation for human diseases were determined based on
annotated OMIM disease phenotypes and phenotypes from Orphanet
(http://omim.org/, http://www.orphadata.org). Disease annotations shared
between the two databases (n= 2485) were used to minimise differences
in annotation by source. We examined phenotypes annotated in both
databases or annotated by either source and we found similar results using
both these methods for missense depletion analyses. Inheritance patterns
were captured from both OMIM and Orphanet, and missense and
synonymous substitution rates were compared between genes causing
diseases of different inheritance pattern. For the 10% of disease genes with
multiple disease inheritance types, inclusion or exclusion of these genes
into different inheritance categories also yielded comparable results in
missense depletion analyses.
Exome data analysis in undiagnosed patients
Exome sequencing was performed using blood samples from individuals
after informed consent. Studies were performed under The UCSF
Committee for Human Subjects Research. Genomic DNA was extracted
and sequencing performed using Illumina HiSeq2500 following exon
capture. Following QC and duplicate marking, variants were aligned to
reference and variants called using GATK. Variants were filtered for
amino-acid alteration and then for o1% minor allele frequency based on
ESP, NIEHS EGP and the Hapmap project. For proband analysis, all variants
meeting these criteria were examined using missense depletion methods
regardless of if the variant/gene had previous annotation. Following
addition of parental exome data, trio analysis was also performed and
de novo, compound heterozygous and inherited heterozygous variants
could be further annotated. Variants were also examined for previous
annotation in HGMD and ClinVar.
Structural analysis of ARF1 variants
For protein structure analyses, amino-acid differences from ESP/ExAC
population and patient variants were visualised on protein crystal
structures using Jmol Viewer using RCSB PDB (http://www.rcsb.org/).
The human ARF1 structure 1R8Q, complexed with sec7 and GDP, was used
to visualise variant positions in structure. Examination of variants in
alternative human structure 1HUR revealed similar results. Amino-acid
potential interactions with GDP-binding site residues were analysed using
Ligand-protein contacts and contacts of structural units (LPC/CSU; http://
ligin.weizmann.ac.il/cgi-bin/lpccsu/LpcCsu.cgi).35 Amino acid to ligand
contact prediction for variant sites is shown in Supplementary Materials.
SIFT, Provean, and Polyphen2 scores for the variants are shown in
Supplementary Table 8. GeneMatcher was used to help study this gene.36
Analysis of ARF1 activation
The effect of p.Y35H on ARF1 was tested by introducing the variant by
site-directed mutagenesis into the ARF1 cDNA plasmid (BC011358). Both
wildtype and mutant plasmids were transfected into cultured 293T cells
(UCSF cell culture facility) using Lipofectamine and total expression
assessed by western blotting for ARF1 following protein quantification. For
assessment of activated ARF1, GST-GGA3 (the binding partner that binds
GDP/GTP-bound ARF1) pulldown was performed on lysates prior to
Western blotting. Processing of samples was performed at 4 degrees and
with incubation with GST-GGA3-PBD for 1 h (ThermoFisher, Waltham, MA,
USA). Positive control for activation was GTP-gamma-S, negative was GDP
per manufacturer's instruction. Western blotting for ARF1 was performed
using rabbit anti-ARF1 antibody (catalogue number 16121, ThermoFisher).
The experiment was performed with three biological replicates.
Statistical analysis
We performed statistical tests using R (http://www.r-project.org). The
two-sample Wilcoxon test or Kruskal–Wallis Rank Sum test for more
categories was used for missense to synonymous ratio comparisons
between categories, as variance between groups was not equal. Bonferroni
multiple testing correction was utilised in functional gene enrichment
testing. Histograms and plots were made with R graphics (http://www.
r-project.org) and the ggplot2 package for R (http://ggplot2.org/).
Code availability
All code is available on request by contacting the corresponding author.
Variant data are being deposited at NCBI.
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